<a href="https://www.fiercebiotech.com/biotech/cancer-focused-parabilis-upsized-670m-ipo-breaks-new-record-biotechs" hreflang="en">Cancer-focused Parabilis’ upsized $670M IPO breaks new record for biotechs</a>
fiercebiotech.com·Jun 10, 2026
Parabilis Medicines has achieved a record-breaking $670 million IPO, the largest in biotech history, by offering 33.5 million shares at $20 each. The funds will primarily be used to advance its cancer treatment pipeline, including a phase 3 trial for its Wnt/β-catenin pathway inhibitor, zolucatetide.
The record-breaking $670 million IPO of Parabilis Medicines signals a renewed investor appetite for biotech IPOs, particularly for companies with innovative platforms like helicon peptides targeting previously undruggable targets. This trend could indicate potential opportunities for investment in early-stage biotech companies with novel therapeutic approaches, especially those focusing on oncology and precision medicine.